SLB N.V. (SLB) Stock Forecast
Data as of May 2, 2026Energy · Current price $56.91 (+0.05%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 15, 2026 | Joe Laetsch | Morgan Stanley | $55.00 | -3.4% |
| Jan 27, 2026 | Sergey Pigarev | Loop Capital Markets | $48.00 | -15.7% |
| Jan 27, 2026 | Josh Silverstein | UBS | $61.00 | +7.2% |
| Jan 26, 2026 | Stephen Gengaro | Stifel Nicolaus | $56.00 | -1.6% |
| Jan 26, 2026 | Keith Mackey | RBC Capital | $54.00 | -5.1% |
| Jan 15, 2026 | Keith Mackey | RBC Capital | $51.00 | -10.4% |
| Jan 14, 2026 | Neil Mehta | Goldman Sachs | $49.00 | -13.9% |
| Dec 17, 2025 | David Anderson | Barclays | $47.00 | -17.4% |
| Dec 11, 2025 | Guillaume Delaby | Bernstein | $52.30 | -8.1% |
| Nov 3, 2025 | Sebastian Erskine | Redburn Partners | $48.00 | -15.7% |
| Oct 21, 2025 | Josh Silverstein | UBS | $44.00 | -22.7% |
| Oct 8, 2025 | Guillaume Delaby | Bernstein | $47.60 | -16.4% |
| Jul 27, 2025 | Lloyd Byrne | Jefferies | $51.00 | -10.4% |
| Jul 16, 2025 | Stephen Gengaro | Stifel Nicolaus | $52.00 | -8.6% |
| Apr 14, 2025 | Charles Minervino | Susquehanna | $48.00 | -15.7% |
| Mar 27, 2025 | Lloyd Byrne | Jefferies | $59.00 | +3.7% |
| Oct 21, 2024 | David Anderson | Barclays | $61.00 | +7.2% |
| Oct 21, 2024 | Bascome Majors | Susquehanna | $56.00 | -1.6% |
| Oct 21, 2024 | Stephen Gengaro | Stifel Nicolaus | $60.00 | +5.4% |
| Oct 21, 2024 | Scott Gruber | Citigroup | $54.00 | -5.1% |
Top Analysts Covering SLB
SLB vs Sector & Market
| Metric | SLB | Energy Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.14 | 2.54 | 2.41 |
| Analyst Count | 35 | 10 | 18 |
| Target Upside | +0.1% | +33.6% | +14.9% |
| P/E Ratio | 32.15 | 30.80 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $36.13B | $36.55B | $37.59B | 19 |
| 2027-12-31 | $37.48B | $39.06B | $41.78B | 19 |
| 2028-12-31 | $41.05B | $41.47B | $41.89B | 14 |
| 2029-03-31 | $9.32B | $9.75B | $10.21B | 7 |
| 2029-06-30 | $9.72B | $10.16B | $10.64B | 10 |
| 2029-09-30 | $10.18B | $10.65B | $11.15B | 7 |
| 2029-12-31 | $10.91B | $11.41B | $11.95B | 9 |
| 2030-03-31 | $9.56B | $10.00B | $10.47B | 9 |
| 2030-06-30 | $9.97B | $10.43B | $10.92B | 7 |
| 2030-09-30 | $10.45B | $10.93B | $11.44B | 7 |
| 2030-12-31 | $11.19B | $11.71B | $12.26B | 13 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $2.55 | $2.70 | $3.06 | 16 |
| 2027-12-31 | $3.10 | $3.33 | $3.65 | 17 |
| 2028-12-31 | $2.66 | $3.77 | $4.81 | 8 |
| 2029-03-31 | $0.80 | $0.85 | $0.91 | 10 |
| 2029-06-30 | $0.88 | $0.93 | $0.99 | 9 |
| 2029-09-30 | $0.96 | $1.02 | $1.08 | 9 |
| 2029-12-31 | $1.09 | $1.16 | $1.23 | 10 |
| 2030-03-31 | $0.85 | $0.90 | $0.96 | 6 |
| 2030-06-30 | $0.93 | $0.98 | $1.04 | 6 |
| 2030-09-30 | $1.01 | $1.08 | $1.14 | 6 |
| 2030-12-31 | $1.15 | $1.22 | $1.30 | 6 |
Frequently Asked Questions
What is the analyst consensus for SLB?
The consensus among 35 analysts covering SLB N.V. (SLB) is Buy with an average price target of $52.95.
What is the highest price target for SLB?
The highest price target for SLB is $81.00, set by Guillaume Delaby at Societe Generale on 2023-12-22.
What is the lowest price target for SLB?
The lowest price target for SLB is $25.00, set by Abhishek Kumar at HSBC on 2021-08-04.
How many analysts cover SLB?
35 analysts have issued ratings for SLB N.V. in the past 12 months.
Is SLB a buy or sell right now?
Based on 35 analyst ratings, SLB has a consensus rating of Buy (2.14/5) with a +0.1% upside to the consensus target of $52.95.
What are the earnings estimates for SLB?
Analysts estimate SLB will report EPS of $2.70 for the period ending 2026-12-31, with revenue estimated at $36.55B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.